Opendata, web and dolomites

CellularNanoMachines SIGNED

Development of Stimuli-Responsive Nanoparticle-carrying T lymphocytes in the Fight against Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "CellularNanoMachines" data sheet

The following table provides information about the project.

Coordinator
KATHOLIEKE UNIVERSITEIT LEUVEN 

Organization address
address: OUDE MARKT 13
city: LEUVEN
postcode: 3000
website: www.kuleuven.be

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 240˙530 €
 EC max contribution 240˙530 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-GF
 Starting year 2019
 Duration (year-month-day) from 2019-01-04   to  2022-01-03

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) coordinator 240˙530.00
2    Sloan-Kettering Institute for Cancer Research CORPORATION US (New York) partner 0.00

Map

 Project objective

The cancer burden represents an overarching health problem and it is essential that EU institutions develop the next generation of diagnostics that overcome the inadequacy of current imaging strategies. Nanomedicine, defined as the use of nanotechnologies in medicine, offers extraordinary opportunities to address these unmet medical needs. The proposed research project endeavours to find effective anticancer diagnostics through the development of smart cellular nano-machines. The design will integrate white blood cells (concretely, tumour-targeted T lymphocytes) as living carriers of stimuli-responsive drug-loaded NPs. The tumour-homing T cells will facilitate NP accumulation in tumours until an internal/external stimulus triggers NP-release. The NPs will also possess imaging capabilities to visualize and monitor the injected formulations and confirm that the designed NPs target cancer cells in vivo. This approach aims to achieve highly versatile, selective and effective nanomedicine products that combine imaging and therapy for different types of cancer (theranostics). The strategy will provide anticancer materials compatible with industrial processes and personalized medicine. Thus, I believe the results arising from this work will place EU institutions in an unbeatable position to capitalize on the next generation of diagnostics, not only to boost the competitiveness of our industries but also to make positive changes in the lives of our citizens.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CELLULARNANOMACHINES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CELLULARNANOMACHINES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

PNAIC (2018)

Positive and Negative Asymmetry in Intergroup Contact: Its Impact on Linguistic Forms of Communication and Physiological Responses

Read More  

TOPOCIRCUS (2019)

Simulations of Topological Phases in Superconducting Circuits

Read More  

MingleIFT (2020)

Multi-color and single-molecule fluorescence imaging of intraflagellar transport in the phasmid chemosensory cilia of C. Elegans

Read More